Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
165,5 SEK | +0,49% | +4,42% | +23,78% |
25/04 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
25/04 | Biotage AB (publ) rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 | CI |
Vakgebied
Aantal werknemers: 669
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Small Molecules & Synthetic Therapeutics
35,1
%
| 770 | 49,1 % | 654 | 35,1 % | -15,06% |
Biologics & Advanced Therapeutics
24,4
%
| 66 | 4,2 % | 454 | 24,4 % | +587,88% |
Analytical Testing
22,3
%
| 382 | 24,4 % | 415 | 22,3 % | +8,64% |
Scale-up
8,2
%
| 181 | 11,6 % | 152 | 8,2 % | -16,02% |
Water & Environmental Testing
7,1
%
| 122 | 7,8 % | 133 | 7,1 % | +9,02% |
Diagnostics
2,9
%
| 46 | 2,9 % | 54 | 2,9 % | +17,39% |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
North and South America
40,2
%
| 660 | 42,1 % | 748 | 40,2 % | +13,33% |
EMEA
39,2
%
| 376 | 24,0 % | 729 | 39,2 % | +93,88% |
China
7,5
%
| 232 | 14,8 % | 139 | 7,5 % | -40,09% |
Japan
6,0
%
| 115 | 7,3 % | 111 | 6,0 % | -3,48% |
South Korea
3,2
%
| 61 | 3,9 % | 60 | 3,2 % | -1,64% |
Other APAC
1,8
%
| - | - | 33 | 1,8 % | - |
India
1,5
%
| 32 | 2,0 % | 27 | 1,5 % | -15,62% |
Sweden
0,8
%
| 18 | 1,1 % | 15 | 0,8 % | -16,67% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | 09-02-06 | |
Andrew Kellett
DFI | Director of Finance/CFO | 56 | 25-09-23 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Magnus Nordstedt
CTO | Chief Tech/Sci/R&D Officer | 54 | 01-01-02 |
Anders Wikström
COO | Chief Operating Officer | 51 | 01-10-02 |
Lisa Egelrud
LAW | General Counsel | 49 | - |
Sales & Marketing | 50 | - | |
Olof Nord
PRN | Corporate Officer/Principal | 49 | - |
Petra Duprez
HRO | Human Resources Officer | 59 | 01-05-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 72 | 09-02-06 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 01-11-19 |
Kieran Murphy
CHM | Chairman | 61 | 04/01 |
Director/Board Member | 69 | - | |
Mark Bradley
BRD | Director/Board Member | 62 | 24-04-19 |
Karen Sørensen
BRD | Director/Board Member | 62 | - |
Daniel Menasco
BRD | Director/Board Member | 47 | 01-01-15 |
Pär Lundgren
BRD | Director/Board Member | 39 | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 80 008 185 | 79 645 985 ( 99,55 %) | 0 | 99,55 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Biotage Sweden AB
Biotage Sweden AB Medical SpecialtiesHealth Technology Part of Biotage AB, Biotage Sweden AB is a Swedish impact tech company committed to solving society ’ s problems. The private company is based in Uppsala, Sweden. The company offers solutions in drug discovery, analytical, water, and environmental testing. Biotage provides workflow solutions and products to customers in drug discovery and development, analytical testing, and water and environmental testing. The company was founded in 1989 by Sheridan G. Snyder. |
Medical Specialties
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,78% | 1,21 mld. | |
-12,91% | 19,08 mld. | |
-46,21% | 2,65 mld. | |
+18,15% | 1,87 mld. | |
-3,12% | 1,61 mld. | |
-10,69% | 1,02 mld. | |
-20,89% | 905 mln. | |
-7,14% | 716 mln. | |
-18,10% | 682 mln. | |
+4,01% | 480 mln. |
- Beurs
- Aandelen
- Koers BIOT
- Onderneming Biotage AB